FAS Wealth Partners’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$749K Buy
12,355
+259
+2% +$15.1K 0.05% 196
2025
Q4
$652K Buy
12,096
+4,933
+69% +$237K 0.04% 208
2025
Q3
$323K Sell
7,163
-71
-1% -$3.32K 0.02% 265
2025
Q2
$335K Buy
7,234
+102
+1% +$5.01K 0.02% 256
2025
Q1
$435K Sell
7,132
-309
-4% -$18K 0.04% 221
2024
Q4
$421K Sell
7,441
-6
-0.1% -$335 0.04% 224
2024
Q3
$385K Buy
7,447
+74
+1% +$3.47K 0.03% 242
2024
Q2
$306K Sell
7,373
-332
-4% -$14.9K 0.03% 251
2024
Q1
$418K Sell
7,705
-285
-4% -$14.5K 0.04% 225
2023
Q4
$410K Sell
7,990
-1,120
-12% -$58.8K 0.04% 215
2023
Q3
$529K Sell
9,110
-309
-3% -$18.9K 0.06% 182
2023
Q2
$602K Sell
9,419
-1,782
-16% -$119K 0.08% 162
2023
Q1
$776K Buy
11,201
+623
+6% +$43.9K 0.08% 163
2022
Q4
$761K Sell
10,578
-685
-6% -$51.6K 0.09% 170
2022
Q3
$801K Buy
11,263
+631
+6% +$45.8K 0.09% 147
2022
Q2
$819K Buy
10,632
+2,897
+37% +$221K 0.09% 147
2022
Q1
$565K Buy
7,735
+248
+3% +$16.7K 0.05% 180
2021
Q4
$467K Sell
7,487
-289
-4% -$17K 0.04% 204
2021
Q3
$460K Sell
7,776
-3,470
-31% -$229K 0.04% 190
2021
Q2
$751K Sell
11,246
-344
-3% -$22.4K 0.07% 152
2021
Q1
$732K Sell
11,590
-148
-1% -$9.21K 0.08% 147
2020
Q4
$728K Buy
11,738
+67
+0.6% +$4.12K 0.08% 141
2020
Q3
$704K Buy
11,671
+712
+6% +$42.9K 0.1% 135
2020
Q2
$644K Buy
10,959
+197
+2% +$11.8K 0.09% 134
2020
Q1
$600K Buy
10,762
+574
+6% +$35.1K 0.1% 122
2019
Q4
$654K Buy
10,188
+668
+7% +$38.3K 0.11% 122
2019
Q3
$483K Buy
9,520
+70
+0.7% +$3.29K 0.09% 132
2019
Q2
$429K Buy
9,450
+67
+0.7% +$3.12K 0.08% 141
2019
Q1
$448K Buy
9,383
+115
+1% +$5.73K 0.09% 135
2018
Q4
$482K Sell
9,268
-542
-6% -$29.1K 0.11% 122
2018
Q3
$609K Buy
9,810
+51
+0.5% +$3.03K 0.14% 97
2018
Q2
$540K Buy
9,759
+56
+0.6% +$3.02K 0.15% 102
2018
Q1
$614K Buy
9,703
+247
+3% +$15.9K 0.18% 92
2017
Q4
$579K Sell
9,456
-21
-0.2% -$1.31K 0.15% 97
2017
Q3
$604K Buy
9,477
+624
+7% +$36.4K 0.17% 87
2017
Q2
$493K Sell
8,853
-452
-5% -$24.6K 0.15% 95
2017
Q1
$506K Sell
9,305
-344
-4% -$18.9K 0.16% 93
2016
Q4
$564K Buy
9,649
+1,069
+12% +$58.4K 0.17% 78
2016
Q3
$463K Buy
8,580
+527
+7% +$33.9K 0.15% 87
2016
Q2
$592K Buy
8,053
+924
+13% +$65.3K 0.22% 64
2016
Q1
$455K Buy
7,129
+335
+5% +$21.1K 0.23% 52
2015
Q4
$467K Buy
6,794
+23
+0.3% +$1.52K 0.23% 64
2015
Q3
$401K Buy
6,771
+610
+10% +$38.7K 0.23% 57
2015
Q2
$410K Buy
6,161
+409
+7% +$27K 0.21% 58
2015
Q1
$371K Buy
5,752
+9
+0.2% +$563 0.19% 58
2014
Q4
$339K Buy
5,743
+10
+0.2% +$564 0.18% 60
2014
Q3
$293K Buy
5,733
+12
+0.2% +$599 0.17% 69
2014
Q2
$278K Buy
5,721
+111
+2% +$5.47K 0.16% 69
2014
Q1
$291K Sell
5,610
-389
-6% -$20.7K 0.2% 62
2013
Q4
$319K Buy
+5,999
New +$306K 0.19% 60

Other funds holding BMY

FAS Wealth Partners's BMY Position: Q1 2026 in Review

FAS Wealth Partners increased its Bristol-Myers Squibb (BMY) stake by 2.1% in Q1 2026, buying an estimated $15.1K and bringing the position to 12,355 shares worth $749K. The position accounts for 0.05% of the portfolio, ranked #196.

FAS Wealth Partners first reported a position in BMY in Q4 2013 and has held it in 50 quarters since. The position peaked at $819K in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • FAS Wealth Partners held 12,355 shares of Bristol-Myers Squibb worth $749K as of Q1 2026.
  • FAS Wealth Partners bought 259 Bristol-Myers Squibb shares in Q1 2026, an estimated $15.1K.
  • Bristol-Myers Squibb made up 0.05% of FAS Wealth Partners's portfolio in Q1 2026, its #196 holding.
  • FAS Wealth Partners first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 50 quarters since.
  • FAS Wealth Partners's Bristol-Myers Squibb position peaked at $819K in Q2 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on FAS Wealth Partners's 13F filing for Q1 2026, filed 10 Jun 2026.